publication date: Dec. 20, 2010

In this issue: 

Research teams link response to Iressa to mutations in EGF receptor.

SPOREs hammer out research agenda, seek $50,000 from NCI for further tissue analysis.

Dramatic responses to Iressa prompted further bench research. Results have limited clinical relevance, for now, but findings may explain failure of INTACT studies.

NCI blocked groups from phase III Iressa studies.

Also in this 8-page issue: Amgen names PhRMA executive Rodger Currie vice president for government affairs.

Robert Hall appointed government relations director for National Coalition for Cancer Survivorship.

Funding opportunities listed.

April issue of Business & Regulatory Report included (8 additional pages).

Download (PDF 375KB)

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.